Abbott Laboratories reported
positive results from a Phase 3 trial evaluating the company's gel treatment
for advanced Parkinson's disease.
Abbott said the study found patients treated with its levodopa-carbidopa
intestinal gel showed clinically meaningful and statistically significant
improvement in "off" time--or periods of poor mobility, slowness and
stiffness--compared with the standard oral treatment. The study also found an
improvement in patients' "on" time--or periods of good motor- symptom
control--without troublesome dyskinetic symptoms.
LCIG contains the same active ingredient as the standard oral treatment, but
comes in a gel form and is administered directly into the small intestine
through a procedurally implanted tube connected to a portable pump. The 12-week
study was conducted to evaluate the efficacy, safety and tolerability of
continuous LCIG infusion in patients with advanced Parkinson's disease.
LCIG, which is currently being evaluated in additional Phase 3 trials in
the U.S., is approved in 40 countries outside the U.S.
Πηγή: DOW JONES NEWSWIRES